Impact of Imatinib Treatment on Renal Function in Chronic Myeloid Leukemia Patients
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F22%3A00125092" target="_blank" >RIV/00216224:14110/22:00125092 - isvavai.cz</a>
Result on the web
<a href="https://onlinelibrary.wiley.com/doi/epdf/10.1111/nep.14014" target="_blank" >https://onlinelibrary.wiley.com/doi/epdf/10.1111/nep.14014</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1111/nep.14014" target="_blank" >10.1111/nep.14014</a>
Alternative languages
Result language
angličtina
Original language name
Impact of Imatinib Treatment on Renal Function in Chronic Myeloid Leukemia Patients
Original language description
Background Recently, multiple epidemiological studies have linked imatinib with the alteration of kidney function in chronic myeloid leukemia (CML) patients. This meta-analysis aimed to summarize the impact of Imatinib use on renal function in CML patients. Methods A systematic search was conducted on MEDLINE and Embase to identify articles assessing the impact of imatinib exposure on renal function in CML patients. The risk of bias was assessed using the Newcastle-Ottawa scale (NOS). Two authors independently performed literature screening, risk of bias, and data extraction. The risk of renal dysfunction (chronic kidney disease or acute kidney injury) among imatinib users was computed as the primary outcome of interest. The certainty of findings was assessed using the GRADE criteria. Results A total of nine articles qualified for inclusion in the systematic review, of which four articles were eligible for meta-analysis. Based on the scoring on NOS, majority of the included studies were found to be of moderate risk of bias. Majority of the studies (n = 6) reported significantly (p <0.05) decrease in estimated glomerular filtration rate (eGFR) after imatinib treatment. The risk of developing renal dysfunction (CKD or AKI) was found to be significantly higher in imatinib users as compared to other TKI (tyrosine kinase inhibitor) users with a pooled relative risk of 2.70 (95% CI: 1.49 – 4.91). Sensitivity analysis also revealed a consistently high risk of renal dysfunction with imatinib use. GRADE criteria revealed low certainty of evidence. Conclusion This meta-analysis found an increased risk of renal dysfunction in imatinib users compared to other TKI users.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30217 - Urology and nephrology
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Nephrology
ISSN
1320-5358
e-ISSN
1440-1797
Volume of the periodical
27
Issue of the periodical within the volume
4
Country of publishing house
US - UNITED STATES
Number of pages
9
Pages from-to
318-326
UT code for WoS article
000739713300001
EID of the result in the Scopus database
2-s2.0-85122290873